Altogether, our work demonstrated the potential of using ODC inhibitors and A1AR inhibitors as a combination therapy for breast cancer, and presented the potential value of the dual inhibitors of ODC and A1AR in treating breast cancer. Here, ODC1 is linked to breast carcinoma.